969 related articles for article (PubMed ID: 17712745)
1. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Micek ST
Clin Infect Dis; 2007 Sep; 45 Suppl 3():S184-90. PubMed ID: 17712745
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.
Maclayton DO; Hall RG
Ann Pharmacother; 2007 Feb; 41(2):235-44. PubMed ID: 17299012
[TBL] [Abstract][Full Text] [Related]
3. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.
Drew RH
Pharmacotherapy; 2007 Feb; 27(2):227-49. PubMed ID: 17253914
[TBL] [Abstract][Full Text] [Related]
4. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
Scheinfeld N
J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
[TBL] [Abstract][Full Text] [Related]
5. Treatment of infections caused by resistant Staphylococcus aureus.
Anstead GM; Quinones-Nazario G; Lewis JS
Methods Mol Biol; 2007; 391():227-58. PubMed ID: 18025681
[TBL] [Abstract][Full Text] [Related]
6. New agents for Staphylococcus aureus endocarditis.
Drees M; Boucher H
Curr Opin Infect Dis; 2006 Dec; 19(6):544-50. PubMed ID: 17075329
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
Jørgen B; Merckoll P; Melby KK
Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care.
Tverdek FP; Crank CW; Segreti J
Crit Care Clin; 2008 Apr; 24(2):249-60, vii-viii. PubMed ID: 18361944
[TBL] [Abstract][Full Text] [Related]
9. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G; Moellering RC
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
[TBL] [Abstract][Full Text] [Related]
10. Key considerations in the treatment of complicated staphylococcal infections.
Jones RN
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
[TBL] [Abstract][Full Text] [Related]
11. Treatment of infections due to resistant Staphylococcus aureus.
Anstead GM; Cadena J; Javeri H
Methods Mol Biol; 2014; 1085():259-309. PubMed ID: 24085702
[TBL] [Abstract][Full Text] [Related]
12. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
Appelbaum PC
Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
French GL
J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
[TBL] [Abstract][Full Text] [Related]
14. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Stevens DL; Herr D; Lampiris H; Hunt JL; Batts DH; Hafkin B
Clin Infect Dis; 2002 Jun; 34(11):1481-90. PubMed ID: 12015695
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection.
Rouse MS; Steckelberg JM; Patel R
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):363-5. PubMed ID: 17449212
[TBL] [Abstract][Full Text] [Related]
16. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.
Saravolatz LD; Pawlak J; Johnson LB
J Antimicrob Chemother; 2007 Aug; 60(2):406-9. PubMed ID: 17586562
[TBL] [Abstract][Full Text] [Related]
17. Alternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Culos KA; Cannon JP; Grim SA
Am J Ther; 2013; 20(2):200-12. PubMed ID: 21642833
[TBL] [Abstract][Full Text] [Related]
18. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.
Stryjewski ME; Chambers HF
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S368-77. PubMed ID: 18462092
[TBL] [Abstract][Full Text] [Related]
19. MRSA--the tip of the iceberg.
Appelbaum PC
Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
[TBL] [Abstract][Full Text] [Related]
20. New treatments for methicillin-resistant Staphylococcus aureus.
Stryjewski ME; Corey GR
Curr Opin Crit Care; 2009 Oct; 15(5):403-12. PubMed ID: 19561492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
